Thomas Andersen

PhD Candidate

Academic article

Show author(s) (2022). Podocan and Adverse Clinical Outcome in Patients Admitted With Suspected Acute Coronary Syndromes. Frontiers in Cardiovascular Medicine. 1-9.

Show author(s) (2019). Pentraxin-3 vs C-reactive Protein and Other Prognostic Biomarkers in Acute Coronary Syndrome: A Substudy of the Platelet Inhibition and Patients Outcomes (PLATO) Trial. European Heart Journal: Acute Cardiovascular Care. 313-322.
Show author(s) (2019). C-X-C ligand 16 is an independent predictor of cardiovascular death and morbidity in acute coronary syndromes. Arteriosclerosis, Thrombosis and Vascular Biology. 2402-2410.

Poster

Show author(s) (2021). Circulation 2021 (Nov. 8); 144 (Suppl. 1): A9149. The novel Wnt-Pathway inhibitor podogan is not associated with all-cause mortality or cardiovascular outcome in patients admitted with suspected acute coronary syndrome. .
Show author(s) (2021). Circulation 2021 (Nov. 8); 144 (Suppl. 1): A12013. Procollagen type-1 N-terminal propeptide, a collagen synthesis biomarker, is associated with adverse clinical outcome in patients with nsuspected acute coronary syndrome. .